Literature DB >> 33923123

Sustained Surface ICAM-1 Expression and Transient PDGF-B Production by Phorbol Myristate Acetate-Activated THP-1 Cells Harboring Blau Syndrome-Associated NOD2 Mutations.

Mizuho Nishiyama1, Hong-Jin Li1, Ikuo Okafuji2, Akihiko Fujisawa3, Mizue Ehara4, Naotomo Kambe3,4, Fukumi Furukawa1, Nobuo Kanazawa1,5.   

Abstract

OBJECTIVES: Blau syndrome is a distinct class of autoinflammatory syndrome presenting with early-onset systemic granulomatosis. Blau syndrome-causing NOD2 mutations located in the central nucleotide-oligomerization domain induce ligand-independent basal NF-κB activation in an in vitro reporter assay. However, the precise role of this signaling on granuloma formation has not yet been clarified.
METHODS: Blau syndrome-causing NOD2 mutations were introduced into human monocytic THP-1 cells, and their morphological and molecular changes from parental cells were analyzed. Identified molecules with altered expression were examined in the patient's lesional skin by immunostaining.
RESULTS: Although the production of proinflammatory cytokines was not altered without stimulation, mutant NOD2-expressing THP-1 cells attached persistently to the culture plate after stimulation with phorbol myristate acetate. Sustained surface ICAM-1 expression was observed in association with this phenomenon, but neither persistent ICAM-1 mRNA expression nor impaired ADAM17 mRNA expression was revealed. However, the transient induction of PDGF-B mRNA expression was specifically observed in stimulated THP-1 derivatives. In the granulomatous skin lesion of a Blau syndrome patient, ICAM-1 and PDGF-B were positively immunostained in NOD2-expressing giant cells.
CONCLUSIONS: Sustained surface ICAM-1 expression and transient PDGF-B production by newly differentiating macrophages harboring mutant NOD2 might play a role in granuloma formation in Blau syndrome.

Entities:  

Keywords:  Blau syndrome; ICAM-1; NOD2 mutation; PDGF-B

Year:  2021        PMID: 33923123     DOI: 10.3390/children8050335

Source DB:  PubMed          Journal:  Children (Basel)        ISSN: 2227-9067


  27 in total

1.  Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases.

Authors:  Mathias Chamaillard; Dana Philpott; Stephen E Girardin; Habib Zouali; Suzanne Lesage; Fabrice Chareyre; The Hung Bui; Marco Giovannini; Ulrich Zaehringer; Virginie Penard-Lacronique; Philippe J Sansonetti; Jean-Pierre Hugot; Gilles Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

2.  Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor.

Authors:  G W Hoyle; J Li; J B Finkelstein; T Eisenberg; J Y Liu; J A Lasky; G Athas; G F Morris; A R Brody
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

3.  CARD15 mutations in Blau syndrome.

Authors:  C Miceli-Richard; S Lesage; M Rybojad; A M Prieur; S Manouvrier-Hanu; R Häfner; M Chamaillard; H Zouali; G Thomas; J P Hugot
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

4.  Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis.

Authors:  B G Marshall; A Wangoo; H T Cook; R J Shaw
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

5.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

6.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

7.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

8.  12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter.

Authors:  A van de Stolpe; E Caldenhoven; B G Stade; L Koenderman; J A Raaijmakers; J P Johnson; P T van der Saag
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

9.  Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism.

Authors:  Kozo Yasui; Masato Yashiro; Mitsuru Tsuge; Akira Manki; Kei Takemoto; Michiko Yamamoto; Tsuneo Morishima
Journal:  Arthritis Rheum       Date:  2010-01

Review 10.  Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.

Authors:  Pleiades T Inaoka; Masato Shono; Mishio Kamada; J Luis Espinoza
Journal:  J Biomed Sci       Date:  2019-06-11       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.